--------------------------------- Join Us! ----------------------------
This year’s roundtable will convene leaders across the healthcare sector to define metrics for advancing transparency, trustworthiness, and patient centricity in medicines development, focusing on the role of the pharmaceutical sector. The discussion will also spotlight and align participants’ ongoing efforts in these areas. Insights from the roundtable may shape future agenda-setting and metrics for the 
Good Pharma Scorecard
.
------------------------------------- Agenda ------------------------------------
8-8:30am
 
Breakfast + Registration
8:30-8:40 
Welcome.
 Jeremy Abbate, Publisher, Scientific American · Arda Ural, Head, Life Sciences, Americas, EY · Lauren Rogge, Principle, Climate Change and Sustainability, EY
8:40-8:55 
Keynote
. 
Yele Aluko
, Chief Medical Officer, EY Americas, 
Reaffirming its Social Contract: BioPharma’s Commitment to Transparency, Accountability and Public Trust
8:55-9:05m 
Setting the Stage. Jennifer Miller
, Co-Director, Program for Biomedical Ethics, Associate Professor, Yale School of Medicine; President, Bioethics International; Founder, Good Pharma Scorecard.
9:05-9:25 
Keynote. 
Robert Califf,
 Former FDA Commissioner, Duke Clinical Research Institute, Duke University School of Medicine, 
Advancing patient and population health responsibly: Essential commitments for BioPharma
9:25-10:30 
Establishing a Global Industry Reporting Standard for Clinical Research Data: Public health, ethics, and business considerations in response to 
Declaration of Helsinki revisions
Moderator. David Leventhal 
*
Francesca Scotti, Clinical Trial Information System, Transparency Lead, EMA 
*
Vasee Moorthy, Senior Advisor, R&D, World Health Organization 
*
Arthur Caplan, NYU School of Medicine *
Ben Rotz, AVP, Global Medical Policy, Strategy & Operations, Eli Lilly 
*
Morgan Hanger, Executive Director, CTTI, Duke School of Medicine 
*
10:30-10:45 Break
10:45-11:55
 
Enhancing Clinical Demographics in Research.
 
This session will examine FDA expectations, stakeholder priorities, and industry performance trends related to demographic representation in clinical trial enrollment. Panelists will explore strategies linked to success and consider whether incorporating leading indicators into the 
Good Pharma Scorecard
 could help recognize and accelerate further improvement.
Moderator. Cris Woolston, Sanofi 
*
Melissa Penn, Director, Patient Engagement R&D, Bayer *confirmed
Ivy Kam, Director DEI Sciences, Regeneron 
*
Lorena Kuri, Global Clinical Trials Strategy and Operations, Bristol Myers Squibb
Andrew Whitehead, BMS
 
*
Osa Eisele, MD, MPH, Head, Representation in Clinical Research, Amgen
Martin Mendoza, Chief Health Population Health Officer, CMS
Tricha Shivas, Chief of Staff and Strategy, Foundation for Sarcoidosis Research
Cary Gross, Professor of Medicine and Public Health, Yale School of Medicine
Pierre Theodore, Executive Director Health Equity, Genentech 
*
Silke Schoch, Director, Research & Programs, National Health Council 
*
11:55-12:15
 
The Bioethics Leadership Forum
 (BLF). What is it and how to get involved?
12:15-12:40 Lunch Break
12:40-12:55 
Keynote 
– Mark McClellan, Former FDA Commissioner, Duke-Margolis Institute for Health Policy
12:55-2pm 
Access to medicines in LMICS: Ethical considerations, barriers, facilitators + global trends
Moderator: Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control (UICC)
Mary Ann Slack, Former Director, FDA Center for Drug Evaluation and Research (CDER)
Vibhooti Ashar, Global Market Access & Pricing, BMS
Alex Schmidt, Head, Vaccine Development, Bill & Melinda Gates Medical Research Institute
2:05pm -3:15 
Patient Centricity in the Pharma Sector: Identifying a Consistent Set of Metrics & the Role of the Good Pharma Scorecard
Moderator: Cosmina Hogea, Global Patient Focused Implementation Science, Gilead
Alan Balch, CEO, Patient Advocate Foundation; National Patient Advocate Foundation
Sneha Dave, Generation Patient 
*confirmed
Linda Kollmar, AVP Patient Innovation and Engagement, Merck
Luther T. Clark, Executive Director, Patient Innovation & Engagement, V&I Global Medical and Scientific Affairs, Merck Research Laboratories
*
Ronika Alexander-Parrish, Director, US Medical Affairs, Pfizer
Mat Phillips, Associate Director, Patient View
Pat Furlong, CEO, Parent Project Muscular Dystrophy
Ellyn Getz, MPH, Director, R&D Patient Partnerships, CSL
Pam Gavin, CEO, NORD
Tré LaRosa, Associate Project Manager, Foundation for the National Institutes of Health
3:15-3:45
 
Linking Bioethics and Patient Centricity Efforts w/ Sustainability, CSR, ESG and Impact Reporting in Life Science Companies:
 How are and should investors, companies and regulators be thinking and communicating about these efforts?
Moderator: Mohit, Partner/Principal, Climate Change and Sustainability Services, EY
Jennifer Evans, Executive Director, Environmental Sustainability & Social Impact, BMS
Smita Pillai, CDO, Regeneron
Jessica Federer, Board Member, Angelini Ventures, Sage Therapuetics, Advisory Board, Yale Blavatnik Fund for Innovation; Member, Yale Institutional Review board
William Stack, ESG, Gilead,
Claudia Carravetta, VP, Corporate Responsibility, President, Abbvie Foundation
Brian Reid,
 
Pharma Pricing and Public Affairs
3:45-4 Break
4-4:25pm 
Small Group Brainstorming Sessions:
 
We will break out into 6 small groups of 10 people each to brainstorm projects, themes/topics, and metrics we should think about collaborating on and developing with the good pharma scorecard to advance bioethics, patient centricity, access, and trustworthiness in medicines development and delivery. Group facilitators:
4:24-4:55pm
 
Full Roundtable Discussions: Where do we go from here? Next steps for advancing, tracking, and communicating patient centricity, trustworthiness, and bioethics progress in pharma.
 
Facilitator: Jennifer Miller
4:55-5pm
 
Closing Remarks
· Jeremy Abbate, Publisher, Scientific American *
confirmed
· Lauren Rogge, Principle, Climate Change and Sustainability, EY
 
*
confirmed
· Arda Ural, Head of Life Sciences, Americas, EY *
confirmed
· Jennifer E. Miller, Co-Director, Associate Professor, Yale School of Medicine, President Bioethics International, Interim-CEO Good Pharma Scorecard
5-6pm Networking and Drinks, with all Participants, sponsored by EY
6-7:30pm Dinner, for speakers and BLF members, sponsored by Bioethics International
About the Roundtable Sponsors + Hosts
Bioethics International (BEI)
 is a 501c3 public charity, founded in 2005, to help advance ethics, trustworthiness, patient-centricity, and social responsibility in healthcare.
EY
. EY’s purpose is building a better working world. The insights and quality services EY provide help build trust and confidence in the capital markets and in economies the world over. They develop outstanding leaders who team to deliver on their promises to all our stakeholders. In so doing, EY plays a critical role in building a better working world for its people, for clients and communities.
Scientific American. 
Scientific American is the authority on science and technology for a general audience, with coverage that explains how research changes our understanding of the world and shapes our lives. First published in 1845, 
Scientific American
 is the longest continuously published magazine in the US. The magazine has published articles by more than 150 Nobel Prize-winning scientists and built a loyal following of influential and forward thinking readers. The archives of 
Scientific American
 include articles penned by Albert Einstein, Thomas Edison, Jonas Salk, Marie Curie, Stephen Hawking, Franklin D. Roosevelt, Stephen Jay Gould, Bill Gates, and more.
Yale Program for Biomedical Ethics. 
The Yale Program for Biomedical Ethics incorporates a diverse group that brings a wide range of experience and expertise to the table, including faculty and staff from the Schools of Medicine, Nursing, Law, Divinity, Public Health, as well as Yale New Haven Hospital staff, and others who share a common interest in education, research, and clinical practice in the field of medical ethics.
 
Our program coordinates the ethics education of Yale medical students over the course of their four years, including assistance for those who choose to write their thesis in this area. In addition, educational programs are provided for other members of the Yale medical community, such as journal clubs, working groups and special conferences.
Good Pharma Scorecard (GPS)
.
 The
 
Good Pharma Scorecard is a ranking and rating of pharmaceutical companies on their bioethics, social responsibility, and patient centricity performance. Through the Scorecard, we develop benchmarks for what constitutes ‘good’ socially responsible practices. We then use these benchmarks to measure and rate company performance annually, helping recognize best practices, catalyze reform where needed, and track progress on goals over time.
Information Source: Yale, EY + Bioethics International | eventbrite

紐約

美國

正在搜尋Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | NYC, NY, USA的資訊及門票嗎？Trip.com 樂意為您服務。立即查看關於Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | NYC, NY, USA的日期、行程及其他資訊，並在參與Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | NYC, NY, USA之前先訂好實惠又合適的機加酒！Trip.com 還準備了更多類似的精彩活動，當然也包含優惠的機票及飯店組合。立即啟程！

Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | NYC, NY, USA的日期及行程 | Trip.com

Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | NYC, NY, USA

Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success | Trip.com

探索更多紐約相關的內容

null | Trip.com

看看您好友的想法？分享您的答案就能開始聊天！

紐約半島飯店

紐約, 鄰近特朗普大廈|中城西區

奢華飯店

洛厄爾飯店

大都會藝術博物館

人氣景點

博物館

特展展廳

M80***23

- 種類繁多：收藏了來自世界各地、跨越5000多年歷史的三百萬件藝術品，涵蓋古埃及、希臘、羅馬、亞洲、非洲、大洋洲等地區的文物，以及歐洲繪畫、雕塑、裝飾藝術等，還有大量美國和現代藝術作品。
​
- 精品眾多：擁有諸多聞名遐邇的藏品，如古埃及的丹鐸神廟、中國的《照夜白》《藥師佛經變圖》等，以及眾多歐洲古代大師的繪畫和雕塑。
 
建築與佈局
 
- 外觀宏偉：新古典主義風格的建築外觀，莊重典雅，與中央公園相得益彰，成為紐約市的標誌性文化建築之一。 
​
- 佈局合理：19個展覽部門分佈在不同樓層和區域，展覽空間寬敞明亮，展品陳列有序，注重營造與展品相契合的展示氛圍，使觀眾能夠更好地欣賞和理解藝術品

自由女神像

明日可用

MathewMorais

這是在紐約時必須做的,trip.com讓自由島週邊遊變得輕鬆愉快。渡輪騎行愉快,博物館有自由女神像,信息非常豐富。地下也位於靠近渡輪站的地方。自由女神像之旅不錯,謝謝trip.com

紐約瑞吉飯店

紐約, 鄰近特朗普大廈|紐約市中心

紐約艾迪遜飯店

紐約四季飯店

帝國大廈

隨買隨用

即日可用

夜景

- 藝術裝飾風格：帝國大廈採用了典型的裝飾藝術風格，強調對稱性、幾何形狀以及精美的裝飾，頂部尖塔設計獨特，使其在紐約的天際線中顯得格外堅挺和獨特。 
​
- 結構設計精妙：建築的骨幹由210根鋼柱構成，其中12根直達建築頂部，為大廈提供了堅實的支撐。隨著高度增加，樓層面積逐漸縮小，形成五個主要變化，這種設計既考慮了結構穩定性，又增加了建築的美觀性。
 
歷史文化價值
 
- 見證歷史變遷：帝國大廈興建於20世紀30年代經濟大蕭條時期，它的建成不僅為當時的美國提供了大量就業機會，也標誌著美國工業的崛起和現代城市發展的巔峰起步。
​
- 承載文化象徵：作為美國的文化象徵之一，帝國大廈出現在眾多電影、文學、藝術作品中，如電影《金剛》，進一步提升了其在全球的知名度和文化影響力。

紐約現代藝術博物館

ryne.srj

紐約必看景點！這麼漂亮、這麼大的博物館，可以了解歷史和藝術！雖然提前到達

中央公園

遊賞秋景好去處

蓝星旅行者

漫步於紐約中央公園，彷彿跌入鋼鐵森林的溫柔裂隙。晨光穿透林梢，在櫻花大道鋪開粉白碎錦，風過時花瓣簌簌落肩，摩天樓的稜角在花影裡柔化成朦朧背景音&nbsp;。

長椅上的城市密碼最是動人。指尖撫過冰涼的椅背，銘牌上簡短的文字藏著紐約客的體溫：&quot;給我的妻子卡羅爾，因為她愛中央公園，而我愛她&quot;&mdash;&mdash;生離死別、年少相逢、母與子的羈絆，都在木紋裡凝結成露&nbsp;。當高中生攤開書本笑鬧在綿羊草坪上，當莎士比亞詩篇的朗誦聲從櫻桃山飄向湖面，這座公園便成了情感的共鳴箱，盛滿超越語言的人間敘事&nbsp;。

午後在The Ramble森林區閉目，鳥鳴與溪水聲織成天然白噪音，忽然懂得奧姆斯特德的深意：這340萬平方米的綠肺，原是獻給&quot;疲憊產業工人的手工藝品&quot;，讓無力遠行的人們在此啜飲自然&nbsp;。黃昏的船屋碼頭最是魔幻，木槳劃碎晚霞染紅的湖面，野鴨從曼哈頓倒影中游過，都市的喧囂在此沉入水底，只餘槳聲燈影裡的呼吸&nbsp;。

「當長椅鐫刻的私語與櫻花雨一同落進掌心，方知這混凝土荒原裡的綠洲，原是紐約寫給世界的散文詩。」&nbsp;

時間：	Jun 24, 2025 (UTC-4) 結束
地點：	NYC, NY, USA